Obesity

Obesity and diabetes are becoming increasingly prevalent worldwide. India has the second-highest number of people with diabetes and the third-highest percentage of obese people. As a result, advanced and novel therapeutic options are required. Tirzepatide is a new drug approved in many countries globally as a once-weekly subcutaneous injectable for type 2 diabetes and obesity. India’s drug regulator, CDSCO, recently approved its marketing nationwide. Herein, we present a brief overview of the key characteristics of Tirzepatide, its advantages, and shortcomings.